Please use this identifier to cite or link to this item: https://open.uns.ac.rs/handle/123456789/10916
Title: Fullerenol - A new nanopharmaceutic?
Authors: Đorđević, Aleksandar 
Bogdanović G.
Issue Date: 1-Dec-2008
Journal: Archive of Oncology
Abstract: Chemical modification of fullerenes to hydrosoluble cluster molecules made fullerenes interesting for biological investigation. Among them, polycarbonated and polyhydroxylated fullerene C60 derivatives showed the most interesting biological activities. In this paper, we present the most important recent results of in vitro and in vivo biological studies with fullerenol C60(OH)24. Fullerenol C60(OH)24 was strong antioxidant it reacted with superoxide anion radical, hydroxy radical and nitrous oxide radical in chemical and biological systems. Fullerenol C60(OH)24 did not inhibit human breast cancer cell growth at concentrations from 0.8 to 3.45 μM, but strongly modulated cytotoxic effects of doxorubicin and cis-platinum after 24 and 48 hours of treatment Radioprotective effects of fullerenol C60(OH)24 were shown in different in vitro and in vivo models. Fullerenol C60(OH)24 (100 mglkg) protected rat heart from doxorubicin toxicity. Biodistribution studies of fulelrenol were also investigated. Accumulating data from the literature and from our studies suggest that fullerenol, as a nanoparticle might be a new promising pharmaceutical in the near future. © 2008, Oncology Institute of Vojvodina, Sremska Kamenica.
URI: https://open.uns.ac.rs/handle/123456789/10916
ISSN: 03547310
DOI: 10.2298/AOO0604042D
Appears in Collections:PMF Publikacije/Publications

Show full item record

SCOPUSTM   
Citations

37
checked on May 10, 2024

Page view(s)

22
Last Week
4
Last month
0
checked on May 10, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.